St. Luke's International Hospital is a general and teaching hospital located in the Tsukiji district of Chūō, Tokyo, Japan.

There are 520 beds in St. Luke's International Hospital.

During the past decade, St. Luke's International Hospital conducted 53 clinical trials. In the 10-year time frame, 53 clinical trials started and 23 clinical trials were completed, i.e. on average, 43.4% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 19 clinical trials were completed. i.e. 79.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "St. Luke's International Hospital" #1 sponsor was "Eli Lilly and Company" with 13 trials, followed by "Amgen" with 4 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored, "Janssen Research & Development, LLC" with 4 trials sponsored and "Pfizer" with 4 trials sponsored. Other sponsors include 34 different institutions and companies that sponsored additional 37 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "St. Luke's International Hospital" #1 collaborator was "Daiichi Sankyo Co., Ltd." with 2 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Tokyo Medical and Dental University" with 2 trials as a collaborator, "Alliance for Clinical Trials in Oncology" with 1 trials as a collaborator and "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include 34 different institutions and companies that were collaborators in the rest 44 trials.

According to Clinical.Site data, the most researched conditions in "St. Luke's International Hospital" are "Breast Cancer" (6 trials), "Systemic Lupus Erythematosus" (6 trials), "Coronary Artery Disease" (5 trials), "Lupus Erythematosus, Systemic" (4 trials) and "Rheumatoid Arthritis" (4 trials). Many other conditions were trialed in "St. Luke's International Hospital" in a lesser frequency.

Most popular intervention types in "St. Luke's International Hospital" are "Drug" (58 trials), "Other" (11 trials), "Biological" (5 trials), "Procedure" (3 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (29 trials), "Baricitinib" (5 trials), "Etrasimod" (3 trials), "Nipocalimab" (3 trials) and "Abemaciclib" (2 trials). Other intervention names were less common.

The vast majority of trials in "St. Luke's International Hospital" are 61 trials for "All" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "St. Luke's International Hospital". undefined are not yet recruiting, 14 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 31 completed trials in St. Luke's International Hospital, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in St. Luke's International Hospital, 3 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 39 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 6 trials that are defined as “Not Applicable".

St. Luke's International Hospital has several departments that took part in Clinical trials: "St. Luke's Internat. Hospital, Breast Surgical Oncology" - 5 trials